CNS Pharmaceuticals, Inc.
CNSPAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 10, 2024 | Maxim Group | Jason McCarthy | $0.50(+226%) | $0.15 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | upgrade | Hold →Buy | Sep 12, 2025 |
| Maxim Group | downgrade | Buy →Hold | Mar 25, 2025 |
| Brookline Capital | maintain | Buy | Feb 2, 2021 |
| Ladenburg Thalmann | maintain | Buy | Aug 24, 2020 |
| Benchmark | maintain | Speculative Buy →Buy | Dec 4, 2019 |
Earnings History
Next report: Nov 18, 2026 · EPS est. $-0.27| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.38 | $-0.24 | — | — |
| May 14, 2026 | $-7.30 | $-5.37 | — | — |
| Mar 31, 2026 | $-5.09 | $-5.09 | — | — |
| Nov 14, 2025 | $-5.76 | $-6.63 | — | — |
| Aug 14, 2025 | $-6.42 | $-9.60 | — | — |
| May 15, 2025 | $-18.97 | $-24.00 | — | — |
| Mar 31, 2025 | $-447.96 | $-87.96 | — | — |
| Nov 14, 2024 | $-150.06 | $-0.10 | — | — |
News
Shares of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP - Get Free Report) traded up 1.5% on Friday. The stock traded as high as $5.40 and last traded at $5.32. Approximately 10,901 shares changed hands during trading, an increase of 190% from the average daily volume of 3,759 shares. The stock had previously closed at $5.24. Analyst Ratings
CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript
Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment Access the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment. Dylan Wenke, Chief Business Officer of CNS Pharmaceut…
Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's strategic transformation that is be…
Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / ACCESS Newswire / August 12, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the second quarter …